Mary Wilson
Well-known member
Published: 10 January 2023
https://doi.org/10.1093/infdis/jiac448
Kathryn Peebles, Robert J Arciuolo, Anthony S Romano, Jessica Sell, Sharon K Greene, Sungwoo Lim, Candace Mulready-Ward, Alexandra Ternier, Brittan Badenhop, Kathleen Blaney,
Joseph E Real, Magdalene Spencer, Tristan D McPherson, Shama Desai Ahuja, Jeanne Sullivan Meissner, Jane R Zucker, Jennifer B Rosen
Abstract
Background
Evidence of COVID-19 vaccine effectiveness among persons with prior SARS-CoV-2 infection is accumulating.
Methods
We evaluated the effect against incident SARS-CoV-2 infection of (1) prior infection without vaccination, (2) vaccination (two doses of Pfizer-BioNTech COVID-19 vaccine) without prior infection, and (3) vaccination after prior infection, all compared with unvaccinated persons without prior infection. We included long-term care facility staff in New York City aged <65 years with weekly SARS-CoV-2 testing during January 21–June 5, 2021. Test results were obtained from state-mandated laboratory reporting. Vaccination status was obtained from the Citywide Immunization Registry. Cox proportional hazards models adjusted for confounding with inverse probability of treatment weights.
Results
Compared with unvaccinated persons without prior infection, incident SARS-CoV-2 infection risk was lower in all groups: 54.6% (95% CI: 38.0, 66.8) lower among unvaccinated, previously infected persons; 80.0% (95% CI: 67.6, 87.7) lower among fully vaccinated persons without prior infection; and 82.4% (95% CI: 70.8, 89.3) lower among persons fully vaccinated after prior infection.
Conclusions
Two doses of Pfizer-BioNTech COVID-19 vaccine reduced SARS-CoV-2 infection risk by ≥80%, and for those with prior infection, increased protection from prior infection alone. These findings support recommendations that all eligible persons, regardless of prior infection, be vaccinated against COVID-19.
https://watermark.silverchair.com/j...1ILXdcq1X6jqepL0jwsb2Db7hGAApSIlIedgRaZyFL2eg
https://doi.org/10.1093/infdis/jiac448
Kathryn Peebles, Robert J Arciuolo, Anthony S Romano, Jessica Sell, Sharon K Greene, Sungwoo Lim, Candace Mulready-Ward, Alexandra Ternier, Brittan Badenhop, Kathleen Blaney,
Joseph E Real, Magdalene Spencer, Tristan D McPherson, Shama Desai Ahuja, Jeanne Sullivan Meissner, Jane R Zucker, Jennifer B Rosen
Abstract
Background
Evidence of COVID-19 vaccine effectiveness among persons with prior SARS-CoV-2 infection is accumulating.
Methods
We evaluated the effect against incident SARS-CoV-2 infection of (1) prior infection without vaccination, (2) vaccination (two doses of Pfizer-BioNTech COVID-19 vaccine) without prior infection, and (3) vaccination after prior infection, all compared with unvaccinated persons without prior infection. We included long-term care facility staff in New York City aged <65 years with weekly SARS-CoV-2 testing during January 21–June 5, 2021. Test results were obtained from state-mandated laboratory reporting. Vaccination status was obtained from the Citywide Immunization Registry. Cox proportional hazards models adjusted for confounding with inverse probability of treatment weights.
Results
Compared with unvaccinated persons without prior infection, incident SARS-CoV-2 infection risk was lower in all groups: 54.6% (95% CI: 38.0, 66.8) lower among unvaccinated, previously infected persons; 80.0% (95% CI: 67.6, 87.7) lower among fully vaccinated persons without prior infection; and 82.4% (95% CI: 70.8, 89.3) lower among persons fully vaccinated after prior infection.
Conclusions
Two doses of Pfizer-BioNTech COVID-19 vaccine reduced SARS-CoV-2 infection risk by ≥80%, and for those with prior infection, increased protection from prior infection alone. These findings support recommendations that all eligible persons, regardless of prior infection, be vaccinated against COVID-19.
https://watermark.silverchair.com/j...1ILXdcq1X6jqepL0jwsb2Db7hGAApSIlIedgRaZyFL2eg